U.S. patent application number 10/135657 was filed with the patent office on 2002-09-05 for method for treatment of canine distemper.
Invention is credited to McMichael, John.
Application Number | 20020123041 10/135657 |
Document ID | / |
Family ID | 22631735 |
Filed Date | 2002-09-05 |
United States Patent
Application |
20020123041 |
Kind Code |
A1 |
McMichael, John |
September 5, 2002 |
Method for treatment of canine distemper
Abstract
The present invention relates to a treatment for animals having
canine distemper by administering a composition comprising an
attenuated canine distemper virus a sub-vaccine virus level
effective to alleviate symptoms canine distemper. The invention
also provides a treatment for animals having canine distemper by
administering a composition comprising an attenuated canine measles
virus a sub-vaccine virus level effective to alleviate symptoms
canine distemper.
Inventors: |
McMichael, John; (Delanson,
NY) |
Correspondence
Address: |
MARSHALL, GERSTEIN & BORUN
6300 SEARS TOWER
233 SOUTH WACKER
CHICAGO
IL
60606-6357
US
|
Family ID: |
22631735 |
Appl. No.: |
10/135657 |
Filed: |
April 30, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10135657 |
Apr 30, 2002 |
|
|
|
09747551 |
Dec 22, 2000 |
|
|
|
6383741 |
|
|
|
|
60173378 |
Dec 28, 1999 |
|
|
|
Current U.S.
Class: |
435/5 ;
424/205.1; 424/212.1; 424/213.1; 424/818; 435/69.3; 435/91.33;
514/44R |
Current CPC
Class: |
A61K 39/12 20130101;
A61K 2039/552 20130101; A61K 2039/70 20130101; C12N 2760/18434
20130101; A61K 39/175 20130101; A61K 2039/5254 20130101; Y10S
424/818 20130101; A61P 31/12 20180101 |
Class at
Publication: |
435/5 ; 435/69.3;
435/91.33; 424/205.1; 424/212.1; 424/213.1; 424/818; 514/44 |
International
Class: |
C12Q 001/70; A61K
031/70; A01N 043/04; C12N 015/09; C12P 019/34; A61K 039/12; A61K
039/165; A61K 039/175 |
Claims
What is claimed:
1. A method for treating a animal suffering from canine distemper
comprising the step of: administering a composition comprising an
attenuated canine distemper virus at a sub-vaccine level effective
to alleviate symptoms of canine distemper.
2. The method of claim 1 wherein said composition comprises from
about 10.sup.-3 TCID.sub.50 to about 500 TCID.sub.50 attenuated
canine distemper virus per dose.
3. The method of claim 1 wherein said composition comprises about 2
TCID.sub.50 attenuated canine distemper virus per dose.
4. The method of claim 1 wherein said composition is administered
to a animal in a single dose of about 0.2 cc in a pharmaceutically
acceptable carrier.
5. The method of claim 1 wherein multiple daily doses of said
composition are administered to the animal.
6. The method of claim 1 where the composition is administered to a
animal by a means selected from the group consisting of
subcutaneously, intravenously and intramuscularly.
7. The method of claim 6 wherein the composition is administered to
a animal subcutaneously.
8. A composition for treatment of the symptoms of canine distemper
comprising an attenuated canine distemper virus at a sub-vaccine
level effective to alleviate symptoms of canine distemper in a
pharmaceutically acceptable carrier.
9. The composition of claim 8 wherein from about 10.sup.-3
TCID.sub.50 to about 500 TCID.sub.50 attenuated canine distemper
virus per dose.
10. The composition of claim 9 which comprises 2 TCID.sub.50
attenuated canine distemper virus per dose.
11. A method for treating a animal suffering from canine distemper
comprising the step of: administering a composition comprising an
attenuated canine measles virus at a sub-vaccine level effective to
alleviate symptoms of canine distemper.
12. The method of claim 11 wherein said composition comprises from
about 10.sup.-3 TCID.sub.50 to about 500 TCID.sub.50 attenuated
canine measles virus per dose.
13. The method of claim 11 wherein said composition comprises about
2 TCID.sub.50 attenuated canine measles virus per dose.
14. The method of claim 11 wherein said composition is administered
to a animal in a single dose of about 0.2 cc in a pharmaceutically
acceptable carrier.
15. The method of claim 11 wherein multiple daily doses of said
composition are administered to the animal.
16. The method of claim 11 where the composition is administered to
a animal by a means selected from the group consisting of
subcutaneously, intravenously and intramuscularly.
17. The method of claim 16 wherein the composition is administered
to a animal subcutaneously.
18. A composition for treatment of the symptoms of canine distemper
comprising an attenuated canine measles virus at a sub-vaccine
level effective to alleviate symptoms of canine distemper in a
pharmaceutically acceptable carrier.
19. The composition of claim 18 wherein from about 10.sup.-3
TCID.sub.50 to about 500 TCID.sub.50 attenuated canine measles
virus per dose.
20. The composition of claim 19 which comprises 2 TCID.sub.50
attenuated canine measles virus per dose.
Description
[0001] This application claims the benefit of U.S. Provisional
Patent Application Serial No. 60/173,378, filed Dec. 28, 1999, the
disclosure of which is hereby incorporated by reference.
BACKGROUND OF THE INVENTION
[0002] This invention relates generally to the treatment of canine
distemper and compositions for use therein.
[0003] Canine distemper is a common and often fatal disease of
dogs. It is caused by a virus and is spread most often when animals
come into contact with the bodily secretions of other animals that
are infected with the disease. Over 50% of adult dogs and 80% of
puppies who become infected with distemper die. Of those that
survive, many will suffer permanent damage to their nervous systems
and will suffer from seizures and paralysis for the remainder of
their lives.
[0004] The symptoms most commonly associated with distemper are red
runny eyes and a nasal discharge. Vomiting, diarrhea and fever soon
develop, followed by various disorders of the nervous system.
Puppies three to six months old are particularly susceptible to the
disease.
[0005] While vaccination with modified live virus vaccines has been
particularly useful in reducing the incidence and spread of the
disease, there are currently no drugs available which will cure or
treat the symptoms of the disease. As with most viruses, supportive
therapy to strengthen and nourish the body and prevent secondary
infection remains the only option for animals that contract
distemper. When recovery does occur, it is a lengthy process and
dogs that survive are left with life-long debilitating conditions.
As a result, most veterinarians recommend euthanasia for dogs who
develop the disease.
[0006] Accordingly, there remains a need for methods of treatment
of canine distemper.
SUMMARY OF THE INVENTION
[0007] The invention provides methods for treating an animal
suffering from canine distemper comprising the step of:
administering a composition comprising an attenuated canine
distemper virus at a sub-vaccine level effective to alleviate
symptoms of canine distemper. A preferred source of attenuated
canine distemper virus and of attenuated canine measles virus for
use according to the invention is the Vanguard.RTM. D-M vaccine
(Pfizer) which contains highly attenuated strains of canine
distemper virus and measles virus.
[0008] The attenuated canine distemper virus and/or attenuated
canine measles virus are administered at sub-vaccine levels.
Sub-vaccine levels are defined as levels less than those sufficient
to induce a protective humoral immune response associated with a
prophylactically effective titre of antibodies. According to one
aspect of the invention, the composition comprises from about
10.sup.-3 TCID.sub.50 to about 500 TCID.sub.50 attenuated canine
distemper virus per dose and preferably two or three doses are
administered daily. More preferably, the composition is
administered at a dosage of about 2 TCID.sub.50 According to one
embodiment of the invention, a 2 TCID.sub.50 dose may be provided
by administration of 0.2 ml of a 1:25 dilution of Vanguard.RTM. D-M
vaccine (Pfizer). Alternatively according to another aspect of the
invention, the composition comprises from about 10.sup.-3
TCID.sub.50 to about 500 TCID.sub.50 attenuated canine measles
virus per dose and preferably two or three doses are administered
daily. More preferably, the composition is administered at a dosage
of about 2 TCID.sub.50.
[0009] The compositions of the invention may be administered to
animals by a variety of suitable methods with means selected from
the group consisting of subcutaneous, intravenous, oral and
intramuscular administration being preferred. Particularly
preferred methods of administration is the subcutaneous methods of
administration. When the composition is administered
subcutaneously, it is preferred that two or three doses be
administered daily.
[0010] According to one preferred method the composition is
administered to a animal in a two or three daily dosages of about
0.2 cc in a pharmaceutically acceptable carrier. Such
pharmaceutically-acceptable carriers include water, saline,
albumin, and dextrose and combinations thereof.
[0011] Compositions of the invention for treatment of the symptoms
of canine distemper comprise canine distemper attenuated vaccine at
a sub-vaccine level effective to alleviate symptoms of canine
distemper in a pharmaceutically acceptable carrier. Preferred
compositions are those which comprise from about from about
10.sup.-3 TCID.sub.50 to about 500 TCID.sub.50 attenuated canine
distemper virus per dose with those comprising about 2 TCID.sub.50
per dose being most preferred. Alternative preferred compositions
according to the invention comprise from about 10.sup.-3
TCID.sub.50 to about 500 TCID.sub.50 attenuated canine measles
virus per dose and preferably two or three doses are administered
daily. More preferably, the composition is administered at a dosage
of about 2 TCID.sub.50.
[0012] Additional aspects and advantages of the invention will
become apparent upon consideration of the following detailed
description thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0013] The present invention relates to the discovery that the
administration of canine distemper attenuated vaccine at a
sub-vaccine levels is effective to alleviate symptoms of canine
distemper. While not wishing to be bound by a particular theory of
invention, it is believed that while the distemper virus certainly
induces the disease, the victim's immune response to the virus
aggravates the disease. Therefore, by selectively controlling the
aberrant response by specific stimulation of a targeted
subpopulation of suppressor T cells, the response can be mitigated
without compromising the animal's ability to combat the virus and
survive. Administration of canine distemper virus according to the
invention functions to accomplish this goal. Moreover, because both
rubeola (measles virus) and canine distemper virus are from the
family paramyxoviridae and the genus morbillivirus they are closely
related and administration of rubeola in subvaccine levels has been
found to alleviate the symptoms of canine distemper virus
infection.
[0014] The following Example illustrates a preferred embodiment of
the invention and provides evidence of the effectiveness of claimed
treatment methods. Numerous improvements and further aspects of the
invention are apparent to the skilled artisan upon consideration of
the Example which follows.
EXAMPLE
[0015] According to this example, twelve dogs suffering from canine
distemper and exhibiting symptoms of lethargy, anorexia, central
nervous system disorders and respiratory disorders were treated
according to the methods of the invention. Specifically, the dogs
were treated by subcutaneous injection two or three times daily
with 0.2 cc of a 1:25 dilution of a commercially available
distemper virus vaccine (Vanguard.RTM. D-M vaccine, Pfizer) The
diluted composition comprises about 2 TCID.sub.50. The symptoms of
eleven of the twelve dogs resolved within 24 to 48 hours and there
were no long term symptoms in any of the recovered dogs.
[0016] Positive results similar to those reported in the Example
were found when canine measles (rubeola) virus was administered to
dogs suffering from distemper in amounts of about 2
TCID.sub.50.
[0017] The invention has been described in terms of its preferred
embodiments and is only intended to be limited by the scope of the
following claims.
* * * * *